 Antibodies, Monoclonal
"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
| Descriptor ID |
D000911
|
| MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 5 | 12 | 17 | | 1997 | 5 | 7 | 12 | | 1998 | 2 | 14 | 16 | | 1999 | 7 | 8 | 15 | | 2000 | 7 | 8 | 15 | | 2001 | 11 | 15 | 26 | | 2002 | 6 | 17 | 23 | | 2003 | 9 | 11 | 20 | | 2004 | 12 | 17 | 29 | | 2005 | 15 | 15 | 30 | | 2006 | 20 | 14 | 34 | | 2007 | 21 | 10 | 31 | | 2008 | 14 | 20 | 34 | | 2009 | 34 | 20 | 54 | | 2010 | 28 | 23 | 51 | | 2011 | 16 | 19 | 35 | | 2012 | 13 | 13 | 26 | | 2013 | 14 | 11 | 25 | | 2014 | 33 | 8 | 41 | | 2015 | 13 | 11 | 24 | | 2016 | 19 | 10 | 29 | | 2017 | 28 | 17 | 45 | | 2018 | 23 | 12 | 35 | | 2019 | 19 | 9 | 28 | | 2020 | 29 | 11 | 40 | | 2021 | 20 | 12 | 32 | | 2022 | 7 | 30 | 37 | | 2023 | 6 | 26 | 32 | | 2024 | 15 | 15 | 30 | | 2025 | 26 | 9 | 35 | | 2026 | 10 | 14 | 24 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Jukema JW, Van Neer NJ, Szarek M, Cobbaert C, Bittner VA, Schwertfeger M, Bhatt DL, Fazio S, Goodman SG, Harrington RA, Stevanovic I, White HD, Steg PG, Schwartz GG. Interleukin-6 and C-reactive protein prognostic value following acute coronary syndrome. Eur Heart J. 2026 Oct 26; 47(40):6008-6017.
-
Horiike A, Wakui H, Sugawara S, Minegishi Y, Tasaka S, Kusumoto S, Sakatani T, Suzuki H, Hosomi Y, Tambo Y, Shimokawa T, Ishida H, Miyauchi E, Naoki K, Fukuhara T, Mura E, Tsurui T, Suzuki R, Iriguchi N, Ishiguro T, Hirasawa Y, Manabe R, Shimokawa M, Ohkuma R, Ariizumi H, Kubota Y, Hamada K, Takenoshita S, Ryu K, Sambe T, Inoue E, Wada S, Yoshimura K, Sagara H, Kobayashi S, Tsunoda T. Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non-Small Cell Lung Cancer with =50% PD-L1 Expression: A Nonrandomized Phase II Trial. Clin Cancer Res. 2026 Oct 15; 32(20):4571-4579.
-
Lindsay HB, Billups CA, Kocak M, Alban TJ, Young Poussaint T, Wong P, Chan TA, Kovacic B, Makarov V, Juric I, Diaz-Montero CM, Srivastava R, Pavicic P, Parthasarathy P, Lenzen A, MacDonald TJ, Pollack IF, Vinitsky A, Robison NJ, Baxter P, Hwang EI, Leggas M, Khalil DN, Fangusaro J, Onar-Thomas A, Dunkel IJ. Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG. Clin Cancer Res. 2026 Oct 01; 32(19):4307-4318.
-
Lemus-Reyes JI, Fernández-Quintero ML, Ayala E, Swanson OM, Good MR, Ji W, Suja D, Han J, Ward AB, Guthmiller JJ. Antigenic and structural analysis of the influenza hemagglutinin lateral patch. J Virol. 2026 Oct 20; 100(10):e0126526.
-
DeRoo J, Terry JS, Zhao N, Stasevich TJ, Snow C, Geiss BJ. Linear antibody epitope prediction using AlphaFold2. Elife. 2026 Sep 18; 13.
-
Callaway HM, Zyla DS, Hastie KM, Harkins SS, Kothalawalage S, Samarasinghe N, Flynn A, Hariharan C, Yin J, Corti D, Bourhy H, Dessain SK, Saphire EO. Antigenic landscape of rabies and related lyssaviruses revealed by cryo-EM. Cell Rep. 2026 Oct 27; 45(10):117993.
-
Bentebibel SE, McGrail DJ, Kochat V, Arslan E, Abdel-Wahab R, Pazdrak B, Murthy R, Tahon NHM, Cho SN, Duose DY, Wani KM, Liu J, Haymaker C, Gomez JA, Sonnemann H, Katailiha AS, Nassif-Rausseo B, Rahim M, Li I, Mayer AT, Yang X, Hsu FJ, Zhang J, Johnson DH, Amaria RN, Glitza Oliva IC, Patel SP, Hwu P, Elsayes KM, Tawbi HA, Burks JK, Bernatchez C, Davies MA, Rai K, Lizée G, Ekmekcioglu S, Diab A. Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study. Cancer Discov. 2026 Sep 01; 16(9):1780-1800.
-
Maeda K, Campbell PL, Wu Q, Tsou PS, Cooney LA, Mao-Draayer Y, Fox DA, Gurrea-Rubio M. Anti-CD6 monoclonal antibody UMCD6 induces CD6 internalization, remodels costimulatory receptor availability, and modulates CD4+ T-cell activation. Front Immunol. 2026; 17:1918840.
-
Budde LE, Kamdar M, Assouline SE, Chavez JC, Ghosh N, Ollila TA, Hodson DJ, Modi D, Bastos-Oreiro M, Naik SG, Nakhoda SK, Lee Batlevi C, Wang J, Makadia S, Kwan A, Penuel E, Jing J, Wu H, Ead W, Pham S, To I, Wei MC, Wang ML. Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study. Blood. 2026 08 06; 148(6):682-692.
-
Galsky MD, Valderrama BP, Maruzzo M, Font A, Ciuleanu T, Chatzkel J, Koie T, Hoimes CJ, Puente J, Zakharia Y, Rosenbaum E, Boehm K, Loriot Y, Bedke J, Powles TB, Necchi A, Wiechno P, Álvarez-Fernández C, Kim TH, Oliveira N, Flaig TW, Wirtz HS, Mihm M, Huang Q, Rogiers A, Homet Moreno B, Gómez de Liaño A. Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer. N Engl J Med. 2026 Jul 23; 395(4):338-348.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|